Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Expert Systems Joins Eilean's PTPN2 Inhibitor Program | Contract Pharma
Breaking News, Collaborations & Alliances

Expert Systems Joins Eilean’s PTPN2 Inhibitor Program

Eilean to leverage Expert Systems’ AI platform to help advance a new pipeline of best-in-class immuno-oncological therapy solutions.

Expert Systems, an expert in AI-enabled drug discovery, has expanded its collaboration with Eilean Therapeutics as it joins its new PTPN2 inhibitor program, which Eilean recently acquired from Ness Therapeutics Inc in an all-equity transaction.
 
Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T cell protein tyrosine phosphatase (TC-PTP), is ubiquitously expressed, primarily in hematopoietic and placental cells. As a critical negative regulator of the JAK-STAT pathway, PTPN2 functions to directly regulate signaling through cytokine receptors, including IFNγ. Thus, enhancing IFNγ sensing and signaling through the inhibition of PTPN2 is a potential therapeutic strategy to improve the efficacy of cancer immunotherapy regimens.
 
“Eilean’s lead PTPN2 inhibitor molecules demonstrate exceptional efficacy, selectivity, oral bioavailability and a good safety profile,” commended Bill Farley, CBO at Expert Systems. “We’re proud to be Eilean’s partner & leverage our cutting-edge AI platform to help advance a new pipeline of best-in-class immuno-oncological therapy solutions with an improved safety and tolerability profile.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters